Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.

Frontiers in immunology - 1 Jan 2024

Tsujikawa Takahiro, Ohno Kazuchika, Morita Kei-Ichi, Saburi Sumiyo, Mitsuda Junichi, Yoshimura Kanako, Kimura Alisa, Morimoto Hiroki, Ogi Hiroshi, Shibata Saya, Akashi Takumi, Kurata Morito, Imoto Issei, Shimizu Yasushi, Kano Satoshi, Watanabe Akihito, Yamazaki Tomoko, Asada Yukinori, Hayashi Ryuichi, Saito Yuki, Ozawa Hiroyuki, Tsukahara Kiyoaki, Oridate Nobuhiko, Sano Daisuke, Horii Arata, Ueki Yushi, Maruo Takashi, Mukoyama Nobuaki, Hanai Nobuhiro, Fukusumi Takahito, Iwai Hiroshi, Fujisawa Takuo, Fujii Takashi, Nibu Ken-Ichi, Iwae Shigemichi, Ueda Tsutomu, Chikuie Nobuyuki, Yasumatsu Ryuji, Matsuo Mioko, Umeno Hirohito, Ono Takeharu, Masuda Muneyuki, Toh Satoshi, Itoh Kyoko, Hirano Shigeru, Asakage Takahiro

Abstract excerpt

Background: In view of improving biomarkers predicting the efficacy of immunotherapy for head and neck squamous cell carcinoma (R/M HNSCC), this multicenter retrospective study aimed to identify clinical, tumor microenvironmental, and genomic factors that are related to therapeutic response to the anti- Programmed cell death protein 1 (PD-1) antibody, nivolumab, in patients with R/M HNSCC. Methods: The study...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Immunological

Share to B7-H1 Antigen

Share to Genomics

Share to Head and Neck Neoplasms

Share to Immune Checkpoint Inhibitors

Share to Nivolumab

Share to Squamous Cell Carcinoma of Head and Neck

Share to Tumor Microenvironment

Source

Open in PubMed Open full text

Identifiers

PMID: 39136017
DOI: 10.3389/fimmu.2024.1390873
PMCID: PMC11317249

Genes

TP53
CDKN2A
SMAD4

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical, genomic and immune microenvironmental determinants of nivolumab response in head and neck squamous cell carcinoma.PMID 39136017Read ↗

Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapySemantic proximity Read ↗

Deciphering the Immune Landscape of Head and Neck Squamous Cell Carcinoma: A Single-Cell Transcriptomic Analysis of Regulatory T Cell Responses to PD-1 Blockade TherapySemantic proximity Read ↗

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma.Semantic proximity Read ↗

Predictive and prognostic factors for immunotherapy response in head and neck squamous cell carcinoma: a narrative review.Semantic proximity Read ↗

Evaluation of Alcohol, Tobacco, and HPV’s Synergistic regulation of Head and Neck Squamous Cell Carcinoma Treatment Response to PD-L1 Checkpoint Inhibitor TreatmentSemantic proximity Read ↗

CD8 + T cell related prognostic risk model and tumor immune environment modulation in HNSCC based on single-cell and bulk RNA sequencingSemantic proximity Read ↗

Identification of Immune-related lncRNA Panel for Predicting Immune Checkpoint Blockade and Prognosis in Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Identification of factors related to immunotherapy efficacy and prognosis in patients with advanced head and neck squamous cell carcinoma.Semantic proximity Read ↗

Association of DNA damage response signals and oxidative stress status with nivolumab efficacy in patients with Head and Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Targeting cellular and molecular drivers of head and neck squamous cell carcinoma: current options and emerging perspectives.Semantic proximity Read ↗

Comprehensive Analysis of Immune Cell Enrichment In The Tumor Microenvironment of Head And Neck Squamous Cell CarcinomaSemantic proximity Read ↗

Why responses to immune checkpoint inhibitors are heterogeneous in head and neck cancers: Contributions from tumor-intrinsic and host-intrinsic factorsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.